细胞因子诱导的杀伤细胞治疗非小细胞肺癌的疗效及影响因素分析

Efficacy and influencing factors of cytokine-induced killer cell therapy for nonsmall cell lung cancer

目的 分析细胞因子诱导的杀伤(CIK)细胞治疗非小细胞肺癌的疗效及影响因素。方法 依据治疗方案的不同将102例非小细胞肺癌患者分为对照组(n=49)和观察组(n=53),对照组患者给予顺铂+紫杉醇化疗,观察组患者给予顺铂+紫杉醇联合CIK细胞治疗。比较两组患者的临床疗效和不良反应,比较观察组中缓解(完全缓解+部分缓解)和未缓解(疾病稳定+疾病进展)患者的临床特征,分析观察组患者接受CIK细胞治疗疗效的影响因素。结果 观察组患者的客观缓解率为54.72%,明显高于对照组患者的20.41%,差异有统计学意义(P﹤0.01);观察组患者的疾病控制率为75.47%,高于对照组患者的51.02%,差异有统计学意义(P﹤0.05)。根据临床疗效评估结果,观察组中,缓解29例和未缓解24例。缓解和未缓解观察组患者性别、吸烟史、病理类型比较,差异均无统计学意义(P﹥0.05);缓解和未缓解观察组患者年龄、美国东部肿瘤协作组(ECOG)体力状况(PS)评分、TNM分期、肿瘤大小比较,差异均有统计学意义(P﹤0.05)。多因素Logistic回归分析结果显示,年龄≥60岁、ECOG PS评分为2分、TNM分期为Ⅳ期、肿瘤大小≥5 cm均是观察组患者接受CIK细胞治疗疗效的独立危险因素(P﹤0.05)。两组患者的不良反应发生情况比较,差异均无统计学意义(P﹥0.05)。结论 CIK细胞治疗非小细胞肺癌的临床疗效确切,且安全性较高。

Objective To analyze the efficacy and influencing factors of cytokine-induced killer(CIK)cell therapy for non-small cell lung cancer(NSCLC).Method A total of 102 patients with non-small cell lung cancer were divided into control group(n=49,treated with cisplatin+paclitaxel chemotherapy)and observation group(n=53,treated with cis-platin+paclitaxel+CIK cell therapy)according to different treatment methods.The clinical efficacy and adverse reac-tions were compared between the two groups.Compared the clinical characteristics of response(complete response+par-tial response)and non-response(stable disease+progressive disease)patients in the observation group,and the factors in-fluencing the efficacy of CIK cell therapy in the observation group were analyzed.Result The objective response rate of the observation group was 54.72%,significantly higher than 20.41%of the control group,the difference was statistically significant(P<0.01).The disease control rate of the observation group was 75.47%,which was higher than 51.02%of the control group,the difference was statistically significant(P<0.05).According to the clinical efficacy evaluation results,in the observation group,there were 29 cases of response and 24 cases of non-response.There were no statistically signifi-cant differences in gender,smoking history,and pathological type between the response and non-response patients of ob-servation group(P>0.05).There were statistically significant differences in age,Eastern Cooperative Oncology Group(ECOG)performance status(PS)score,TNM staging,and tumor size between the response and non-response patients of observation group(P<0.05).Multivariate Logistic regression analysis showed that age≥60 years,ECOG PS score of 2 points,TNM stage IV,and tumor size≥5 cm were independent risk factors for the efficacy of CIK cell therapy in the ob-servation group of patients(P<0.05).Conclusion The clinical efficacy and safety of CIK cell therapy for non-small cell lungcancerare reliable.